J Korean Ophthalmol Soc.  2010 Feb;51(2):292-296. 10.3341/jkos.2010.51.2.292.

Argon Laser Photocoagulation Combined With Subconjunctival and Intravitreal Bevacizumab Injections for a Retrocorneal Neovascular Membrane

• Kim MS
• Kim JM
• Choi CY

• KMID: 2213155
• DOI: http://doi.org/10.3341/jkos.2010.51.2.292

Abstract

PURPOSE
To report a case of retrocorneal membrane effectively treated with focal argon laser photocoagulation combined with subconjunctival and intravitreal bevacizumab injections.
CASE SUMMARY
A 69-year-old female presented with persistent ocular pain and decreased visual acuity of the right eye following a complicated extracapsular cataract extraction performed nine months earliet. On examination, there was a neovascular retrocorneal membrane covering the superior one-third of the cornea with a sutured wound along the limbus. Following unresponsive conservative treatment, we performed focal argon laser photocoagulation followed by subconjunctival and intravitreal bevacizumab injections (1.25 mg). Two weeks later, markedly regressed neovascularization was noted. Additional argon laser photocoagulation, subconjunctival and intravitreal bavacizumab were performed six weeks later. Four months after the last treatment, the neovascular component substantially decreased and fibrous scar tissue replaced the neovascularization. The retrocorneal membrane showed no progression.

Keyword

Bevacizumab; Laser photocoagulation; Retrocorneal membrane

MeSH Terms

Aged
Antibodies, Monoclonal, Humanized
Argon
Cataract Extraction
Cicatrix
Cornea
Eye
Female
Humans
Light Coagulation
Membranes
Visual Acuity
Bevacizumab
Antibodies, Monoclonal, Humanized
Argon

Figure

• 

  Figure 1. (A) Neovascular retrocorneal membrane was noted along the superior limbus. (B) The neovascularization was noted to be regressing with exudates 2 weeks after the intravitreal and subconjunctival bevacizumab injections followed by focal argon laser photocoagulation. (C) Two months after the last injection, exudates decreased and slight vascular engorgement was noted. (D) Four months after the last injection, neovascular component substantially decreased and fibrous scar tissue replace the neovascularization. The retrocorneal membrane showed no progression in the extent.

Reference

References

1. Michels RG, Kenyon KR, Maumenee AE. Retrocorneal fibrous membrane. Invest Ophthalmol Vis Sci. 1972; 11:822–31.

2. Bloomfield SE, Jakobiec FA, Iwamoto T. Fibrous ingrowth with retrocorneal membrane. Ophthalmology. 1981; 88:459–65.

3. Kremer I, Rapuano CJ, Cohen EJ, et al. Retrocorneal fibrous aberrationss in failed corneal grafts. Am J Ophthalmol. 1993; 115:478–83.

4. Chiou AG, Chang C, Kaufman SC, et al. Characterization of aberrations retrocorneal membrane by confocal microscopy. Cornea. 1998; 17:669–71.

5. Lifshitz T, Oshry T, Rosenthal G. Retrocorneal membrane after penetrating keratoplasty. Ophthalmic Surg Lasers. 2001; 32:159–61.

6. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006; 90:1344–9.

7. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother. 2007; 41:614–25.

8. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal aberrations (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007; 27:439–44.

9. Aisenbrey S, Ziemssen F, Volker M, et al. Intravitreal aberrations (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp aberrations. 2007; 245:941–8.

10. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 2009; 23:117–23.

11. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal aberrations (Avastin) in the treatment of proliferative diabetic aberrations. Ophthalmology. 2006; 113:1695.

12. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea. 2008; 27:992–5.

13. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008; 115:e33–8.

14. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival aberrations injection for corneal neovascularization. Cornea. 2008; 27:142–7.

15. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol. 2007; 125:834–6.

16. Theobald GD, Haas JS. Epithelial invasion of the anterior aberrations following cataract extraction. Trans Am Acad Ophthalmol Otolaryngol. 1948; 52:470–85.

17. Vargas LG, Vroman DT, Solomon KD, et al. Epithelial aberrations after clear cornea phacoemulsification: report of two cases and review of the literature. Ophthalmology. 2002; 109:2331–5.

18. Lee BL, Gaton DD, Weinreb RN. Epithelial downgrowth aberrations phacoemulsification through a clear cornea. Arch aberrations. 1999; 117:283.

19. Weiner MJ, Trentacoste J, Pon DM, Albert DM. Epithelial downgrowth: a 30-year clinicopathological review. Br J Ophthalmol. 1989; 73:6–11.

20. Tomlins PJ, Savant V, Quinlan M. Failure of intracameral fluorouracil to resolve an epithelial ingrowth following clear corneal cataract surgery. J Cataract Refract Surg. 2007; 33:923–4.

21. Schaeffer AR, Nalbandian RM, Brigham DW, O'Donnell FE Jr. Epithelial downgrowth following wound dehiscence after aberrations cataract extraction and posterior chamber lens aberrations: surgical management. J Cataract Refract Surg. 1989; 15:437–41.

22. Loane ME, Weinreb RN. Glaucoma secondary to epithelial aberrations and 5-fluorouracil. Ophthalmic Surg. 1990; 21:704–6.

23. Lai MM, Haller JA. Resolution of epithelial ingrowth in a patient treated with 5-fluorouracil. Am J Ophthalmol. 2002; 133:562–4.

24. Mandelcorn M, Men G. Viscoelastic displacement of fibrous ingrowth: a new surgical approach to retrocorneal membranes. Can J Ophthalmol. 2001; 36:341–3.

25. Chang JH, Gabison EE, Kato T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001; 12:242–9.

26. Philipp W, Speicher L, Humpel C. Expression of vascular aberrations growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000; 41:2514–22.

27. Kvanta A, Sarman S, Fagerholm P, et al. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res. 2000; 70:419–28.

28. Ratel D, Mihoubi S, Beaulieu E, et al. VEGF increases the aberrations activity of endothelial cells within fibrin matrices: aberrations of VEGFR-2, tissue type plasminogen activator and matrix metalloproteinases. Thromb Res. 2007; 121:203–12.

29. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of aberrations bevacizumab (Avastin). Ophthalmology. 2007; 114:855–9.

30. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of Beva- cizumab After Topical, Subconjunctival and Intravitreal aberrations In Rabbits. Invest Ophthalmol Vis Sci. 2009; 50:4807–13.

31. Schoenwald RD. Ocular pharmacokinetics. Textbook of ocular pharmacology. Philadelphia: Lippincott-Raven Publishers;1997. p. 119–38.